Genetic Influence of Meningioma on Cisplatin Resistance: a Mendelian Randomization Analysis

Overview

Journal Int J Clin Pharm

Publisher Springer

Specialties Pharmacology
Pharmacy

Date 2024 Jun 20

PMID 38902470

Authors

Kefu Yu

Ziming Li

Weizhong Shi

Shuxian Yang

Zhigang Zhao

Li Yang

Affiliations

Soon will be listed here.

Abstract

Background: Although various aspects of cisplatin resistance have been studied, the impact of genetic variations still needs to be explored.

Aim: This study aimed to investigate the impact of cisplatin on meningiomas using a two-sample Mendelian randomization (MR) approach, employing genetic variants associated with cisplatin use as instrumental variables.

Method: We conducted a two-sample MR analysis using genome-wide association study (GWAS) data. Instrumental variables were derived from single-nucleotide polymorphisms (SNPs) associated with meningioma to estimate the causal relationship with cisplatin resistance. Sensitivity analyses were performed to confirm the findings.

Results: Genetic predisposition to meningioma significantly increased the risk of cisplatin resistance (odds ratio (OR): 1.63; 95% confidence interval (CI) 1.44-1.85, P < 0.05). Sensitivity analyses supported the causal link.

Conclusion: This MR study suggests that genetic predisposition to meningioma increases susceptibility to cisplatin resistance. Further research is needed to uncover the mechanisms behind these causal effects.

References

Stinchcombe T . Flashback Foreword: Cisplatin/Pemetrexed in Non-Small-Cell Lung Cancer. J Clin Oncol. 2023; 41(14):2455-2456. DOI: 10.1200/JCO.22.02804. View

Patil V, Noronha V, Menon N, Singh A, Ghosh-Laskar S, Budrukkar A . Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation. J Clin Oncol. 2023; 41(13):2350-2361. DOI: 10.1200/JCO.22.00980. View

Lin F, Li X, Wang X, Sun H, Wang Z, Wang X . Stanniocalcin 1 promotes metastasis, lipid metabolism and cisplatin chemoresistance via the FOXC2/ITGB6 signaling axis in ovarian cancer. J Exp Clin Cancer Res. 2022; 41(1):129. PMC: 8988421. DOI: 10.1186/s13046-022-02315-3. View

de Vries G, Rosas-Plaza X, van Vugt M, Gietema J, de Jong S . Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities. Cancer Treat Rev. 2020; 88:102054. DOI: 10.1016/j.ctrv.2020.102054. View

Ghosh S . Cisplatin: The first metal based anticancer drug. Bioorg Chem. 2019; 88:102925. DOI: 10.1016/j.bioorg.2019.102925. View

Kong Y, Dreaden E, Morandell S, Zhou W, Dhara S, Sriram G . Enhancing chemotherapy response through augmented synthetic lethality by co-targeting nucleotide excision repair and cell-cycle checkpoints. Nat Commun. 2020; 11(1):4124. PMC: 7431578. DOI: 10.1038/s41467-020-17958-z. View

Huntoon K, Shaw Toland A, Dahiya S . Meningioma: A Review of Clinicopathological and Molecular Aspects. Front Oncol. 2020; 10:579599. PMC: 7645220. DOI: 10.3389/fonc.2020.579599. View

Ogasawara C, Philbrick B, Adamson D . Meningioma: A Review of Epidemiology, Pathology, Diagnosis, Treatment, and Future Directions. Biomedicines. 2021; 9(3). PMC: 8004084. DOI: 10.3390/biomedicines9030319. View

Apra C, Peyre M, Kalamarides M . Current treatment options for meningioma. Expert Rev Neurother. 2018; 18(3):241-249. DOI: 10.1080/14737175.2018.1429920. View

10.

Sun S, Hawasli A, Huang J, Chicoine M, Kim A . An evidence-based treatment algorithm for the management of WHO Grade II and III meningiomas. Neurosurg Focus. 2015; 38(3):E3. DOI: 10.3171/2015.1.FOCUS14757. View

11.

Al-Khalaf H, Lach B, Allam A, Hassounah M, Alkhani A, Elkum N . Expression of survivin and p16(INK4a)/Cdk6/pRB proteins and induction of apoptosis in response to radiation and cisplatin in meningioma cells. Brain Res. 2007; 1188:25-34. DOI: 10.1016/j.brainres.2007.10.074. View

12.

Ference B, Holmes M, Davey Smith G . Using Mendelian Randomization to Improve the Design of Randomized Trials. Cold Spring Harb Perspect Med. 2021; 11(7). PMC: 8247560. DOI: 10.1101/cshperspect.a040980. View

13.

Mulford A, Wing C, Dolan M, Wheeler H . Genetically regulated expression underlies cellular sensitivity to chemotherapy in diverse populations. Hum Mol Genet. 2021; 30(3-4):305-317. PMC: 8248963. DOI: 10.1093/hmg/ddab029. View

14.

Burgess S, Thompson S . Bias in causal estimates from Mendelian randomization studies with weak instruments. Stat Med. 2011; 30(11):1312-23. DOI: 10.1002/sim.4197. View

15.

Burgess S, Butterworth A, Thompson S . Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013; 37(7):658-65. PMC: 4377079. DOI: 10.1002/gepi.21758. View

16.

Verbanck M, Chen C, Neale B, Do R . Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018; 50(5):693-698. PMC: 6083837. DOI: 10.1038/s41588-018-0099-7. View

17.

Yu C, Wang Z, Sun Z, Zhang L, Zhang W, Xu Y . Platinum-Based Combination Therapy: Molecular Rationale, Current Clinical Uses, and Future Perspectives. J Med Chem. 2020; 63(22):13397-13412. DOI: 10.1021/acs.jmedchem.0c00950. View

18.

Richardson D, Eskander R, OMalley D . Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review. JAMA Oncol. 2023; 9(6):851-859. DOI: 10.1001/jamaoncol.2023.0197. View

19.

Amable L . Cisplatin resistance and opportunities for precision medicine. Pharmacol Res. 2016; 106:27-36. DOI: 10.1016/j.phrs.2016.01.001. View

20.

Sui Q, Chen Z, Hu Z, Huang Y, Liang J, Bi G . Cisplatin resistance-related multi-omics differences and the establishment of machine learning models. J Transl Med. 2022; 20(1):171. PMC: 9004122. DOI: 10.1186/s12967-022-03372-0. View